Prodia Diagnostic Line Tbk vs Graha Mitra Asia Tbk. — how do they compare? Prodia Diagnostic Line Tbk trades at Rp236 (market cap 428.75B, 13.83M 24h volume), while Graha Mitra Asia Tbk. trades at Rp37 (market cap 223.39B, 6.4M 24h volume). The key difference: Prodia Diagnostic Line Tbk is the larger of the two by market cap, and Prodia Diagnostic Line Tbk is more actively traded (13.83M versus 6.4M). Which is the better fit depends on your goals.
| PRDL | RELF | |
|---|---|---|
Market Cap | 428.75B | 223.39B |
Volume | 13.83M | 6.4M |
Lot | 138.27K | 63.97K |
Turnover | 3.27B | 237.95M |
Average Price | 236.62 | 37.2 |
Value | 3.27B | 237.95M |
Indicative Equilibrium Price | 236 | 37 |
Indicative Equilibrium Volume | 1.74K | 6.03K |
Trailing returns across standard periods
Latest headlines on both assets
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →PT Graha Mitra Asia Tbk (hereinafter referred to as the "Company") was established based on Deed No. 15 dated 17 April 2018 issued by Notary Susi Aprilina, SH MKn. The Company started its commercial operations in 2018.
Read more on RELF →